Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. Using ibrutinib data from the RESONATE-2 (PCYC-1115/1116) study conducted in patients ≥65 years without del(17p), we performed a cross-trial comparison with CIT data from published phase 3 studies in first-line treatment of CLL. Progression-free survival (PFS), overall survival (OS), and safety data for ibrutinib (median follow-up 35.7 months) were evaluated alongside available CIT data. CIT regimens included: fludarabine + cyclophosphamide + rituximab (CLL8, CLL10), bendamustine + rituximab (CLL10), obinutuzumab + chlorambucil an...
Background: chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexis...
One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL) deals wi...
Limited information is available on the efficacy of front-line bendamustine and rituximab (BR) in ch...
Chemoimmunotherapy (CIT) and targeted therapy with single‐agent ibrutinib are both recommended first...
BackgroundData regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standa...
Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
BackgroundChronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisti...
Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
BACKGROUND: Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with stan...
BACKGROUND : Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexi...
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
BACKGROUND : Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexi...
Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditi...
The safety and efficacy of ibrutinib, an oral inhibitor of Bruton tyrosine kinase, were evaluated wi...
Background: chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexis...
One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL) deals wi...
Limited information is available on the efficacy of front-line bendamustine and rituximab (BR) in ch...
Chemoimmunotherapy (CIT) and targeted therapy with single‐agent ibrutinib are both recommended first...
BackgroundData regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standa...
Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
BackgroundChronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisti...
Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
BACKGROUND: Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with stan...
BACKGROUND : Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexi...
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
BACKGROUND : Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexi...
Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditi...
The safety and efficacy of ibrutinib, an oral inhibitor of Bruton tyrosine kinase, were evaluated wi...
Background: chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexis...
One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL) deals wi...
Limited information is available on the efficacy of front-line bendamustine and rituximab (BR) in ch...